Tresnak Daniel T, Hackel Benjamin J
Department of Chemical Engineering and Materials Science, University of Minnesota-Twin Cities, Minneapolis, Minnesota, USA.
Department of Chemical Engineering and Materials Science, University of Minnesota-Twin Cities, Minneapolis, Minnesota, USA
Appl Environ Microbiol. 2020 Oct 28;86(22). doi: 10.1128/AEM.01646-20.
Class IIa bacteriocin antimicrobial peptides (AMPs) are a compelling alternative to current antimicrobials because of potential specific activity toward antibiotic-resistant bacteria, including vancomycin-resistant enterococci. Engineering of these molecules would be enhanced by a better understanding of AMP sequence-activity relationships to improve efficacy and limit effects of off-target activity. Toward this goal, we experimentally evaluated 210 natural and variant class IIa bacteriocins for antimicrobial activity against six strains of enterococci. Inhibitory activity was ridge regressed to AMP sequence to predict performance, achieving an area under the curve of 0.70 and demonstrating the potential of statistical models for identifying and designing AMPs. Active AMPs were individually produced and evaluated against eight enterococcus strains and four strains to elucidate trends in susceptibility. It was determined that the mannose phosphotransferase system (manPTS) sequence is informative of susceptibility to class IIa bacteriocins, yet other factors, such as membrane composition, also contribute strongly to susceptibility. A broadly potent bacteriocin variant (lactocin DT1) from a genome was identified as the only variant with inhibitory activity toward all tested strains, while a novel enterocin variant (DT2) from an genome demonstrated specificity toward strains. Eight AMPs were evaluated for proteolytic stability to trypsin, chymotrypsin, and pepsin, and three C-terminal disulfide-containing variants, including divercin V41, were identified as compelling for future studies, given their high potency and proteolytic stability. Class IIa bacteriocin antimicrobial peptides (AMPs), an alternative to traditional small-molecule antibiotics, are capable of selective activity toward various Gram-positive bacteria, limiting negative side effects associated with broad-spectrum activity. This selective activity is achieved through targeting of the mannose phosphotransferase system (manPTS) of a subset of Gram-positive bacteria, although factors affecting this mechanism are not entirely understood. Peptides identified from genomic data, as well as variants of previously characterized AMPs, can offer insight into how peptide sequence affects activity and selectivity. The experimental methods presented here identify promising potent and selective bacteriocins for further evaluation, highlight the potential of simple computational modeling for prediction of AMP performance, and demonstrate that factors beyond manPTS sequence affect bacterial susceptibility to class IIa bacteriocins.
IIa类细菌素抗菌肽(AMPs)是现有抗菌药物的一种极具吸引力的替代品,因为它们可能对包括耐万古霉素肠球菌在内的耐药细菌具有特异性活性。通过更好地理解AMP序列-活性关系来提高疗效并限制脱靶活性的影响,将有助于这些分子的工程改造。为实现这一目标,我们对210种天然和变体IIa类细菌素针对六种肠球菌菌株的抗菌活性进行了实验评估。将抑制活性与AMP序列进行岭回归以预测性能,曲线下面积达到0.70,证明了统计模型在鉴定和设计AMPs方面的潜力。对活性AMPs进行单独生产,并针对八种肠球菌菌株和四种其他菌株进行评估,以阐明敏感性趋势。已确定甘露糖磷酸转移酶系统(manPTS)序列可反映对IIa类细菌素的敏感性,但其他因素,如膜组成,也对敏感性有很大影响。从一个基因组中鉴定出一种具有广泛活性的细菌素变体(乳酸乳球菌素DT1),它是唯一对所有测试菌株都具有抑制活性的变体,而从另一个基因组中发现的一种新型肠球菌素变体(DT2)对特定菌株具有特异性。评估了八种AMPs对胰蛋白酶、胰凝乳蛋白酶和胃蛋白酶的蛋白水解稳定性,鉴于其高效性和蛋白水解稳定性,包括双歧菌素V41在内的三种含C末端二硫键的变体被确定为未来研究的有力候选对象。IIa类细菌素抗菌肽(AMPs)作为传统小分子抗生素的替代品,能够对各种革兰氏阳性细菌具有选择性活性,限制了与广谱活性相关的负面副作用。这种选择性活性是通过靶向一部分革兰氏阳性细菌的甘露糖磷酸转移酶系统(manPTS)实现的,尽管影响该机制的因素尚未完全了解。从基因组数据中鉴定出的肽以及先前表征的AMPs的变体,可以深入了解肽序列如何影响活性和选择性。本文介绍的实验方法鉴定出了有前景的强效和选择性细菌素以供进一步评估,突出了简单计算模型在预测AMP性能方面的潜力,并证明除manPTS序列外的其他因素也会影响细菌对IIa类细菌素的敏感性。